Dormosedan, 20 cc | Free Shipping | EntirelyPets Rx
EPRX Logo
Licensed U.S. Pet Pharmacy | Verified Pharmacy
Mobile Menu
Search Submit
Live Chat My Account
View Cart 0

Sitewide SALE!  GET 18% Off!  Use Code PRES18 *

  • Product ImageProduct Image

Dormosedan, 20 cc

Item# IWM002558
FREE SHIPPING Over $79! * Pet Food & Other Exclusions
QTY:-+

Price too low to show

Add to cart to see low price
$493.95$642.99
RX
  1. We'll ask for your vet's info during check out.
  2. We'll verify your prescription and ship your order! Learn more >>
Recurring Saings in EprxAUTOSHIP & SAVE[Details]
Recurring Saings in EprxAUTOSHIP & SAVE[Details]
  • Description
  • Ingredients
  • Directions
  • FAQ
  • Reviews

Description

Dormosedan for Horses, 20 cc (detomidine hydrochloride) is a nonnarcotic, synthetic equine sedative and analgesic that contains the active ingredient detomidine hydrochloride.

Medical Use

Use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings.

Animals Treated

Horses

Key Benefits

  • Predictable and effect sedation
  • Non-narcotic sedation with a wide margin of safety
  • Simple dosing with 1 or 2 mL per 1,100 lbs horse
  • 80-100x greater potency than xylazine
  • Effects can be maintained for up to 2 hours

Ingredients

Active ingredient

Detomidine Hydrochloride

Directions

View Dormosedan Injection product label.

Dosage and Administration

For Sedation

Administer Dormosedan IV or IM at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan per 100 kg or 220 lb), depending on the depth and duration of sedation required. Onset of sedative effects should be reached within 2-4 minutes after IV administration and 3-5 minutes after IM administration. Twenty mcg/kg will provide 30-90 minutes of sedation and 40 mcg/kg will provide appromixately 90 to 2 hours of sedation.

For Analgesia

Administer Dormosedan IV or IM at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan per 100 kg or 220 lb), depending on the depth and duration of sedation required. Twenty mcg/kg will usually begin to take effect in 2-4 minutes and provide 30-45 minutes of analgesia. The 40 mcg/kg dose will also begin to take effect 204 minutes and provide 45-75 minutes of analgesia.

For Both Sedation and Analgesia

Administer Dormosedan IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan IV per 100 kg or 220 lb), depending on the depth and duration of sedation and analgesia required.

Before and after injection, the animal should be allowed to rest quietly.

Storage

Store at controlled room temperature 15=30° C (59-86° F) in the absence of light. Keep away from pets and children.

Overdosage

Detomidine hydrochloride is tolerated in horses at up to 200 mcg/kg of body weight (10 times the low dosage and 5 times the high dosage). In safety studies in horses, detomidine hydrochloride at 400 mcg/kg of body weight administered daily for 3 consecutive days produced microscopic foci of myocardial necrosis in 1 of 8 horses.

Human Safety Information

Buscopan is not recommended for use in horses intended for food. Not for human use. Keep out of reach of children.

Precautions

Before administration, careful consideration should be given to administering Dormosedan to horses approaching or in endotoxic or traumatic shock, to horses with advanced liver or kidney disease, or to horses under stress from extreme heat, cold, fatigue, or high altitude. Protect treated horses from temperature extremes. Some horses, although apparently deeply sedated, may still respond to external stimuli. Routine safety measures should be employed to protect practitioners and handlers. Allowing the horse to stand quietly for 5 minutes before administration and for 10-15 minutes after injection may improve the response to Dormosedan.

Dormosedan is a potent ?2-agonist, and extreme caution should be exercised in its use with other sedative or analgesic drugs for they may produce additive effects.

When using any analgesic to help alleviate abdominal pain, a complete physical examination and diagnostic work-up are necessary to determine the etiology of the pain.

Food and water should be withheld until the sedative effect of Dormosedan has worn off.

Contraindications

Dormosedan should not be used in horses with pre-existing AV or SA block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal dysrhythmias may occur.

Possible Side Effects

Horses treated with Dormosedan exhibit hypertension. Bradycardia routinely occurs 1 minute after injection. The relationship between hypertension and bradycardia is consistent with an adaptive baroreceptor response to the increased pressure and inconsistent with a primary drug-induced bradycardia. Piloerection, sweating, salivation, and slight muscle tremors are frequently seen after administration. Partial transient penis prolapse may be seen. Partial AV and SA blocks may occur with decreased heart and respiratory rates. Urination typically occurs during recovery at about 45-60 minutes posttreatment, depending on dosage. Incoordination or staggering is usually seen only during the first 3-5 minutes after injection, until animals have secured a firm footing.

Because of continued lowering of the head during sedation, mucus discharges from the nose and, occasionally, edema of the head and face may be seen. Holding the head in a slightly elevated position generally prevents these effects.

FAQ

Dormosedan is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings. It requires a prescription from your veterinarian. Dormosedan is a potent α2-agonist, and extreme caution should be exercised in its use with other sedative or analgesic drugs for they may produce additive effects. When using any analgesic to help alleviate abdominal pain, a complete physical examination and diagnostic work-up are necessary to determine the etiology of the pain. Food and water should be withheld until the sedative effect of Dormosedan has worn off.
Tell your veterinarian if you're planning on breeding your horse or if your mare is pregnant or lactating. Consult with your veterinarian if your horse is currently using any sedatives or analgesics. Let your veterinarian know if your horse has a hypersensitivity to detomidine hydrochloride or other sedatives or analgesics.
Dormosedan should be administered intramuscularly or intravenously. Syringe is not included. Follow your veterinarian's instructions exactly as directed. Before administration, careful consideration should be given to horses approaching or in endotoxic or traumatic shock, to horses with advanced liver or kidney disease, or to horses under stress from extreme heat, cold, fatigue, or high altitude. Protect treated horses from temperature extremes. Some horses, although apparently deeply sedated, may still respond to external stimuli. Routine safety measures should be employed to protect practitioners and handlers. Allowing the horse to stand quietly for 5 minutes before administration and for 10-15 minutes after injection may improve the response to Dormosedan.
Occasional reports of anaphylactic-like reactions have been received, including 1 or more of the following: urticarial (hives), skin plaques, dyspnea, edema (swelling) of the upper airways, trembling, and recumbency (leaning/lying down). Reports of mild adverse reactions have resolved uneventfully without treatment. Severe adverse reactions should be treated symptomatically. Horses treated with Dormosedan exhibit hypertension. Bradycardia (slow heart action) routinely occurs 1 minute after injection. The relationship between hypertension and bradycardia is consistent with an adaptive baroreceptor response to the increased pressure and inconsistent with a primary drug-induced bradycardia. Piloerection (bristling of hairs), sweating, salivation, and slight muscle tremors are frequently seen after administration. Partial transient penis prolapse may be seen. Urination typically occurs during recovery about 45-60 minutes post treatment, depending on dosage. Incoordination or staggering is usually seen only during the first 3-5 minutes after injection, until animals have secured a firm footing. Because of continued lowering of the head during sedation, mucus discharges from the nose and, occasionally, edema of the head and face may be seen. Holding the head in a slightly elevated position generally prevents these effects.
Dormosedan (detomidine hydrochloride) is tolerated in horses at up to 200 mcg/kg of body weight (10 times the low dosage and 5 times the high dosage). In safety studies, detomidine hydrochloride at 400 mcg/kg of body weight administered daily for 3 consecutive days produced microscopic foci of myocardial necrosis in 1 of 8 horses.
Protect treated horses from temperature extremes. Food and water should be withheld until the sedative effect of Dormosedan has worn off.
Dormosedan is a potent α2-agonist, and extreme caution should be exercised in its use with other sedative or analgesic drugs for they may produce additive effects. The use of epinephrine should be avoided since epinephrine may potentiate the effects of α2-agonists.
Your pharmacist has additional information about phenylbutazone written for health professionals that you may read.

Customers Who Bought Also Bought